| Literature DB >> 2645482 |
Abstract
Increased levels of cholesterol, LDL-cholesterol, and VLDL-cholesterol are known risk factors for the development of coronary artery disease. There are multiple drugs that can be used for lowering cholesterol, including lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme step in cholesterol synthesis in the body. The pharmacology of this novel agent is discussed in this article.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2645482 DOI： 10.1016/s0025-7125(16)30681-2
Source DB: PubMed Journal: Med Clin North Am ISSN： 0025-7125 Impact factor: 5.456